nach oben

Erschienen in:

2016 | OriginalPaper | Buchkapitel

1. Eisen

verfasst von : Priv.-Doz. Dr. med. Dr. rer. nat. Peter Nielsen

Erschienen in: Transfusionsassoziierte Pharmakotherapie

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

Eisen ist ein essentielles Spurenelement, wichtig vor allem für die Hämoglobinsynthese. Eisenmangel mit und ohne Anämie stellt perioperativ einen Risikofaktor für Morbidität und Mortalität dar und sollte vor elektiven Operationen diagnostiziert und behandelt werden. Eisensubstitution ist wirksamer vor als nach einer Operation, weil die postoperative Zytokinausschüttung den Erythropoietin- und Eisenstoffwechsel hemmen kann. Eine perioperative Eisensubstitution wird aktuell in vielen Studien untersucht, wobei die Datenlage bisher sehr heterogen ist und wenig signifikante Aussagen zulässt. Orale Eisentherapie ist nur bei akutem Eisenmangel oder begleitend bei der Eigenblutgewinnung vor der OP gut wirksam. Postoperativ ist die Eisenabsorption einige Zeit gehemmt und eine Eisensubstitution wenig effektiv. Eine intravenöse Eisensubstitution in hoher Dosierung (1000 mg – mit und ohne rHuEPO) sollte mit besonderer Sorgfalt eingesetzt werden (sehr selten anaphylaktische Reaktionen).

Bothwell TH, Charlton RW, Cook JD, Finch CA. Iron metabolism in man. Blackwell Scientific Publications, 1979

Brock JH, Halliday JW, Pippard MJ, Powell LW. Iron metabolism in health and disease. WB Saunders Company Ltd. London, Tokyo 1994

Hallberg L. Perspectives on nutritional iron deficiency. Annu Rev Nutr 2001;21:1–21CrossRefPubMed

Gulec S, Anderson GJ, Collins JF. Mechanistic and regulatory aspects of intestinal iron absorption. Am J Physiol Gastrointest Liver Physiol. 2014 Aug 15;307(4):G397-409. doi: 10.1152/ajpgi.00348.2013. Epub 2014

Gunshin H, Mackenzie B, Berger UV, Gunshin Y, Romero MF, Boron WF, Nussberger S, Gollan JL, Hediger M. Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature 1997;388:482–488CrossRefPubMed

Garrick MD, Dolan KG, Horbinski C, Ghio AJ, Higgins D, Porubcin M, Moore EG, Hainsworth LN, Umbreit JN, Conrad ME, Feng L, Lis A, Roth JA, Singleton S and Garrick LM. DMT1. A mammalian transporter for multiple metals. BioMetals 2003;16:41–54CrossRefPubMed

Shawki A, Knight PB, Maliken BD, Niespodzany EJ, Mackenzie B. H(+)-coupled divalent metal-ion transporter-1: functional properties, physiological roles and therapeutics. Curr Top Membr. 2012;70:169–214. doi: 10.1016/B978-0-12-394316-3.00005-3CrossRefPubMed

Zijp IM, Korver O, Tijburg LB. Effect of tea and other dietary factors on iron absorption. Crit Rev Food Sci Nutr. 2000 Sep;40(5):371–98. DOI: 10.1080/10408690091189194CrossRefPubMed

Shayeghi M, Latunde-Dada GO, Oakhill JS, et al. Identificationof an intestinal heme transporter. Cell 2005; 122: 789–801CrossRefPubMed

10.

Donovan A, Brownlie A, Zhou Y, Shepard J, Pratt SJ, Moynihan J, Paw BH, Drejer A, Barut B, Zapata A, Law TC, Brugnara C, Lux SE, Pinkus GS, Pinkus JL, Kingsley PD, Palis J, Fleming MD, Andrews NC, Zon LI. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature 2000;403:776–781CrossRefPubMed

11.

Kühn LC. Iron regulatory proteins and their role in controlling iron metabolism. Metallomics, 2015, DOI: 10.1039/C4MT00164H

12.

Vulpe CD, Kuo YM, Murphy TL, Cowley L, Askwith C, et al. Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse. Nat Genet 21: 195–199. (1999)CrossRefPubMed

13.

Ganz T. Systemic iron homeostasis. Physiol Rev. 2013 Oct;93(4):1721–41. doi: 10.1152/physrev.00008.2013CrossRefPubMed

14.

Frazer DM, Anderson GJ. The regulation of iron transport. Biofactors. 2014 40(2):206–14. doi: 10.1002/biof.1148. Epub 2013 Oct 17

15.

Nai A, Lidonnici MR, Rausa M, Mandelli G, Pagani A, Silvestri L, Ferrari G, Camaschella C. The second transferrin receptor regulates red blood cell production in mice. Blood. 2014 Dec 11. pii: blood-2014-08–596254

16.

Cohen LA, Gutierrez L, Weiss A, Leichtmann-Bardoogo Y, Zhang DL, Crooks DR, Sougrat R, Morgenstern A, Galy B, Hentze MW, Lazaro FJ, Rouault TA, Meyron-Holtz EG. Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway. Blood. 2010;116(9):1574–84. doi: 10.1182/blood-2009-11-253815

17.

Sanchez M, Galy B, Schwanhaeusser B, Blake J, Bähr-Ivacevic T, Benes V, Selbach M, Muckenthaler MU, Hentze MW. Iron regulatory protein-1 and -2: transcriptome-wide definition of binding mRNAs and shaping of the cellular proteome by iron regulatory proteins. Blood. 2011 Nov 24;118(22):e168–79. doi: 10.1182/blood-2011-04-343541CrossRefPubMed

18.

Wilkinson N, Pantopoulos K. The IRP/IRE system in vivo: insights from mouse models. Front Pharmacol. 2014 Jul 28;5:176. doi: 10.3389/fphar.2014.00176

19.

Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, Loreal O. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 2001;276:7811–7819. 11, doi: 10.1074/jbc.M008923200

20.

Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014 Jul;46(7):678–84. doi: 10.1038/ng.2996. Epub 2014 Jun 1PubMedCentralCrossRefPubMed

21.

Pietrangelo A. Hemochromatosis: an endocrine liver disease. Hepatology. 2007 Oct;46(4):1291–301. DOI: 10.1002/hep.21886CrossRefPubMed

22.

Kroot JJ, van Herwaarden AE, Tjalsma H, Jansen RT, Hendriks JC, Swinkels DW. Second round robin for plasma hepcidin methods: first steps toward harmonization. Am J Hematol. 2012 Oct;87(10):977–83. doi: 10.1002/ajh.23289. Epub 2012 Aug 7CrossRefPubMed

23.

Du X1, She E, Gelbart T, Truksa J, Lee P, Xia Y, Khovananth K, Mudd S, Mann N, Moresco EM, Beutler E, Beutler B. The serine protease TMPRSS6 is required to sense iron deficiency. Science. 2008 320(5879):1088–92. doi: 10.1126/science.1157121PubMedCentralCrossRefPubMed

24.

Lehmberg K, Grosse R, Muckenthaler MU, Altamura S, Nielsen P, Schmid H, Graubner U, Oyen F, Zeller W, Schneppenheim R, Janka GE. Administration of recombinant erythropoietin alone does not improve the phenotype in iron refractory iron deficiency anemia patients. Ann Hematol. 2013 92(3):387–94. doi: 10.1007/s00277-012-1618-8CrossRefPubMed

25.

Stoltzfus RJ. Iron deficiency: global prevalence and consequences. Food Nutr Bull. 2003 Dec;24(4 Suppl):S99–103CrossRefPubMed

26.

Schümann K. Safety aspects of iron in food. Ann Nutr Metab. 2001;45(3):91–101CrossRefPubMed

27.

Nielsen P, Benn HP, Peters C, Fischer R, Darda C, Knoedler B, Gabbe EE, Kuehnl P. Iron Status in Prospective Blood Donors Infusionsther Transfusionsmed 1995;22:142–144 DOI:10.1159/000223219

28.

Bothwell TH. Iron requirements in pregnancy and strategies to meet them. Am J Clin Nutr. 2000 Jul;72(1 Suppl):257S–264SPubMed

29.

Spencer B. Blood donor iron status: are we bleeding them dry? Curr Opin Hematol. 2013 20(6):533–9. doi: 10.1097/MOH.0b013e32836589f2CrossRefPubMed

30.

Kim BS, Li BT, Engel A, Samra JS, Clarke S, Norton ID, Li AE. Diagnosis of gastrointestinal bleeding: A practical guide for clinicians. World J Gastrointest Pathophysiol. 2014 Nov 15;5(4):467–78. doi: 10.4291/wjgp.v5.i4.467

31.

Lin S, Rockey DC. Obscure gastrointestinal bleeding. Gastroenterol Clin North Am. 2005 34(4):679–98. doi:10.1016/j.gtc.2005.08.005

32.

Spencer BR, Kleinman S, Wright DJ, Glynn SA, Rye DB, Kiss JE, Mast AE, Cable RG; REDS-II RISE Analysis Group. Restless legs syndrome, pica, and iron status in blood donors. Transfusion. 2013 Aug;53(8):1645–52. doi: 10.1111/trf.12260PubMedCentralCrossRefPubMed

33.

Lozoff B, Smith JB, Kaciroti N, Clark KM, Guevara S, Jimenez E. Functional significance of early-life iron deficiency: outcomes at 25 years. J Pediatr. 2013 Nov;163(5):1260–6. doi: 10.1016/j.jpeds.2013.05.015CrossRefPubMed

34.

Murray-Kolb LE1, Beard JL. Iron treatment normalizes cognitive functioning in young women. Am J Clin Nutr. 2007 Mar;85(3):778–87PubMed

35.

Trost LB, Bergfeld WF, Calogeras E. The diagnosis and treatment of iron deficiency and its potential relationship to hair loss. J Am Acad Dermatol. 2006 May;54(5):824–44CrossRefPubMed

36.

Earley CJ, Connor J, Garcia-Borreguero D, Jenner P, Winkelman J, Zee PC, Allen R. Altered Brain iron homeostasis and dopaminergic function in Restless Legs Syndrome (Willis-Ekbom Disease). Sleep Med. 2014 Nov;15(11):1288–1301. doi: 10.1016/j.sleep.2014.05.009CrossRefPubMed

37.

Leitlinien der Deutschen Gesellschaft für Neurologie. Restless Legs Syndrom (RLS) und Periodic Limb Movement. Disorder (PLMD). http://www.awmf.org/uploads/tx_szleitlinien/030-081l_S1_Restless-Legs-Syndrom_RLS_2012_1.pdf

38.

Kaup M, Dassler K, Weise C, Fuchs H. Shedding of the transferrin receptor is mediated constitutively by an integral membrane metalloprotease sensitive to tumor necrosis factor alpha protease inhibitor-2. J Biol Chem. 2002 Oct 11;277(41):38494–502. doi: 10.1074/jbc.M203461200CrossRefPubMed

39.

Cook JD, Flowers CH, Skikne BS. The quantitative assessment of body iron. Blood. 2003 May 1;101(9):3359–64. DOI 10.1182/blood-2002-10-3071CrossRefPubMed

40.

Thomas C, Thomas L. Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency. Clin Chem. 2002 Jul;48(7):1066–76PubMed

41.

Thomas C, Kobold U, Balan S, Roeddiger R, Thomas L. Serum hepcidin-25 may replace the ferritin index in the Thomas plot in assessing iron status in anemic patients. Int J Lab Hematol. 2011 Apr;33(2):187–93. doi: 10.1111/j.1751-553X.2010.01265.xCrossRefPubMed

42.

Kroot JJ, Tjalsma H, Fleming RE, Swinkels DW. Hepcidin in human iron disorders: diagnostic implications. Clin Chem. 2011 57(12):1650–69. doi: 10.1373/clinchem.2009.140053

43.

Hausmann K, Kuse R, Meinecke KH, Bartels H, Heinrich HC. Diagnostic criteria of prelatent, latent and manifest iron deficiency. Klin Wochenschr. 1971 Nov 1;49(21):1164–74CrossRefPubMed

44.

Cavill I, Macdougall IC. Functional iron deficiency. Blood. 1993 Aug 15;82(4):1377PubMed

45.

Thomas DW, Hinchliffe RF, Briggs C, Macdougall IC, Littlewood T, Cavill I; British Committee for Standards in Haematology. Guideline for the laboratory diagnosis of functional iron deficiency. Br J Haematol. 2013 Jun;161(5):639–48. doi: 10.1111/bjh.12311. Epub 2013 Apr 10CrossRefPubMed

46.

Weiss G. Iron metabolism in the anemia of chronic disease. Biochim Biophys Acta. 2009;1790(7): 682–693CrossRefPubMed

47.

Ruchala P, Nemeth E. The pathophysiology and pharmacology of hepcidin. Trends Pharmacol Sci. 2014 Mar;35(3):155–61. doi: 10.1016/j.tips.2014.01.004PubMedCentralCrossRefPubMed

48.

Poli M, Asperti M, Ruzzenenti P, Regoni M, Arosio P. Hepcidin antagonists for potential treatments of disorders with hepcidin excess. Front Pharmacol. 2014 Apr 28;5:86. doi: 10.3389/fphar.2014.00086. eCollection 2014. Review

49.

van Eijk LT John AS Schwoebel F Summo L Vauléon S Zöllner S Laarakkers CM Kox M van der Hoeven JG Swinkels DW Riecke K Pickkers P. Effect of the antihepcidin Spiegelmer lexaptepid on inflammation-induced decrease in serum iron in humans. Blood. 2014 Oct 23;124(17):2643–6. doi: 10.1182/blood-2014-03-559484PubMedCentralCrossRefPubMed

50.

Kautz L, Jung G, Nemeth E, Ganz T. Erythroferrone contributes to recovery from anemia of inflammation. Blood. 2014 Oct 16;124(16):2569–74. doi: 10.1182/blood-2014-06-584607PubMedCentralCrossRefPubMed

51.

Heinrich HC. Bioverfügbarkeit und therapeutische Wirksamkeit oraler Eisen(II)- und Eisen(III)präparate. Schweiz. Apotheker-Zeitung 1986;22:1231–1256

52.

Wienk KJH, Marx JJM, Beynen AC. The concept of iron bioavailability and its assessment Eur J Nutr 1999; 38: 51–75CrossRefPubMed

53.

Nielsen P, Kongi R, Zimmermann I, Gabbe EE. Bioverfügbarkeit von oralen Eisenpräparaten. In-vitro-Freisetzung von Eisen als einfaches und schnelles Prüfverfahren. Der Allgemeinarzt 1997, 6:524–527; 7:621–626

54.

Haska J, Heimpel H, Metzgeroth. Leitlinien Eisenmangel und Eisenmangelanämie — Onkopedia. https://www.dgho-onkopedia.de/de/onkopedia/leitlinien/eisenmangel-und-eisenmangelanaemie

55.

Kiss H, Konnaris C. Eisenmangelanämie in der Schwangerschaft und post partum - Leitlinie der Universitätsklinik für Frauenheilkunde Wien, eingereicht als Leitlinie der OEGGG. Speculum – Zeitschrift für Gynäkologie und Geburtshilfe 2011; 29 (1)

56.

De-Regil LM, Jefferds ME, Sylvetsky AC, Dowswell T. Intermittent iron supplementation for improving nutrition and development in children under 12 years of age. Cochrane Database Syst Rev. 2011 7;(12):CD009085. doi: 10.1002/14651858.CD009085.pub2

57.

Fütterer S1, Andrusenko I, Kolb U, Hofmeister W, Langguth P. Structural characterization of iron oxide/hydroxide nanoparticles in nine different parenteral drugs for the treatment of iron deficiency anaemia by electron diffraction (ED) and X-ray powder diffraction (XRPD). J Pharm Biomed Anal. 2013 Dec;86:151–60. doi: 10.1016/j.jpba.2013.08.005

58.

Funk F, Ryle P, Canclini C, Neiser S, Geisser P. The new generation of intravenous iron: chemistry, pharmacology, and toxicology of ferric carboxymaltose. Arzneimittelforschung. 2010;60(6a):345–53. doi: 10.1055/s-0031-1296299

59.

Albaramki J, Hodson EM, Craig JC et al. Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database Syst. Rev. 2012; (1): Cd007857

60.

Locatelli F, Bárány P, Covic A, De Francisco A, Del Vecchio L, Goldsmith D, Hörl W, London G, Vanholder R, Van Biesen W; ERA-EDTA ERBP Advisory Board. Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transplant. 2013 Jun;28(6):1346–59. doi: 10.1093/ndt/gft033CrossRefPubMed

61.

Ganzoni AM. Eisen-Dextran intravenös: therapeutische und experimentelle Möglichkeiten. Schweiz Med Wochenschr 1970; 100: 301–3PubMed

62.

Musallam KM, Tamim HM, Richards T, et al. Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study. Lancet 2011; 378: 1396–407CrossRefPubMed

63.

Baron DM, Hochrieser H, Posch M, Metnitz B, Rhodes A, Moreno RP, Pearse RM, Metnitz P; European Surgical Outcomes Study (EuSOS) group for Trials Groups of European Society of Intensive Care Medicine; European Society of Anaesthesiology. Preoperative anaemia is associated with poor clinical outcome in non-cardiac surgery patients. Br J Anaesth. 2014 Sep;113(3):416–23. doi: 10.1093/bja/aeu098. Epub 2014 May 14CrossRefPubMed

64.

Theusinger OM. A WHO concept- patient blood management. Praxis (Bern 1994). 2014 Oct 15;103(21):1257–62. doi: 10.1024/1661-8157/a001801

65.

Clevenger B, Richards T. Pre-operative anaemia. Anaesthesia 2015, 70 (Suppl. 1), 20–28 doi:10.1111/anae.12918CrossRefPubMed

66.

Singh S, Gudzenko V, Fink MP. Pathophysiology of perioperative anaemia. Best Pract Res Clin Anaesthesiol. 2012 Dec;26(4):431–9. doi: 10.1016/j.bpa.2012.11.002CrossRefPubMed

67.

Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Abraham E, MacIntyre NR, Shabot MM, Duh MS, Shapiro MJ. The CRIT Study: Anemia and blood transfusion in the critically ill–current clinical practice in the United States. Crit Care Med. 2004 Jan;32(1):39–52CrossRefPubMed

68.

Lin DM1, Lin ES, Tran MH. Efficacy and safety of erythropoietin and intravenous iron in perioperative blood management: a systematic review. Transfus Med Rev. 2013 Oct;27(4):221–34. doi: 10.1016/j.tmrv.2013.09.001CrossRefPubMed

69.

Poli, M. et al. (2011) Heparin: a potent inhibitor of hepcidin expression in vitro and in vivo. Blood 117, 997–1004CrossRefPubMed

70.

Müller MM, Fischer D, Stock U, Geisen C, Steffen B, Nussbaumer J, Meybohm P. Patient blood management–The preoperative patient. Anasthesiol Intensivmed Notfallmed Schmerzther. 2014 Apr;49(4):246–53;. doi: 10.1055/s-0034-1373804CrossRefPubMed

71.

Patel KV Epidemiology of anemia in older adults. Semin.Hematol. (2008. 45, 210–217. doi:10.1053/j.seminhematol.2008.06.006

72.

Guralnik JM, Eisenstaedt RS, Ferrucci L, Klein HG, Woodman RC. Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood 2004;104:2263–2268CrossRefPubMed

73.

Saleh E1, McClelland DB, Hay A, Semple D, Walsh TS. Prevalence of anaemia before major joint arthroplasty and the potential impact of preoperative investigation and correction on perioperative blood transfusions. Br J Anaesth. 2007 Dec;99(6):801–8CrossRefPubMed

74.

Hung M, Ortmann E, Besser M, Martin-Cabrera P, Richards T, Ghosh M, Bottrill F, Collier T, Klein AA. A prospective observational cohort study to identify the causes of anaemia and association with outcome in cardiac surgical patients. Heart. 2015 Jan 15;101(2):107–12. doi: 10.1136/heartjnl-2014-305856. Epub 2014 Sep 12CrossRefPubMed

75.

Park KH, Sawada T, Kosuge T, Kita J, Shimoda M, Tomosugi N, Kubota K. Surgical inflammation induces hepcidin production after abdominal surgery. World J Surg. 2012 Apr;36(4):800–6. doi: 10.1007/s00268-012-1473-8CrossRefPubMed

76.

Henry DA, Carless PA, Moxey AJ, O'Connell D, Forgie MA, Wells PS, Fergusson D. Pre-operative autologous donation for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev. 2002;(2):CD003602. Review

77.

Goodnough LT. The role of iron in erythropoiesis in the absence and presence of erythropoietin therapy. Nephrol Dial Transplant. 2002;17 Suppl 5:14–8CrossRefPubMed

78.

Bovy C, Baudoux E, Salmon JP, Beguin Y. Increased iron absorption during autologous blood donation supported by recombinant human erythropoietin therapy. Transfusion. 2006 Sep;46(9):1616–23CrossRefPubMed

79.

Takami Y, Masumoto H. Predictors of allogenic blood transfusion in elective cardiac surgery after preoperative autologous blood donation. Surg Today. 2009;39(4):306–9. doi: 10.1007/s00595-008-3893-5CrossRefPubMed

80.

Bezwada HP, Nazarian DG, Henry DH, Booth RE Jr. Preoperative use of recombinant human erythropoietin before total joint arthroplasty. J Bone Joint Surg Am. 2003 Sep;85-A(9):1795–800PubMed

81.

Billote DB, Glisson SN, Green D, Wixson RL. A prospective, randomized study of preoperative autologous donation for hip replacement surgery. J Bone Joint Surg Am. 2002 Aug;84-A(8):1299–304PubMed

82.

Weisbach V, Skoda P, Rippel R, Lauer G, Glaser A, Zingsem J, Zimmermann R, Eckstein R. Oral or intravenous iron as an adjuvant to autologous blood donation in elective surgery: a randomized, controlled study. Transfusion. 1999 May;39(5):465–72CrossRefPubMed

83.

Lidder PG, Sanders G, Whitehead E, Douie WJ, Mellor N, Lewis SJ, Hosie KB. Pre-operative oral iron supplementation reduces blood transfusion in colorectal surgery - a prospective, randomised, controlled trial. Ann R Coll Surg Engl. 2007 May;89(4):418–21PubMedCentralCrossRefPubMed

84.

Quinn M, Drummond RJ, Ross F, Murray J, Murphy J, Macdonald A. Short course pre-operative ferrous sulphate supplementation–is it worthwhile in patients with colorectal cancer? Ann R Coll Surg Engl. 2010 Oct;92(7):569–72. doi: 10.1308/003588410X12699663904277PubMedCentralCrossRefPubMed

85.

Lachance K, Savoie M, Bernard M, Rochon S, Fafard J, Robitaille R, Vendittoli PA, Lévesque S, de Denus S. Oral ferrous sulfate does not increase preoperative hemoglobin in patients scheduled for hip or knee arthroplasty. Ann Pharmacother. 2011 Jun;45(6):764–70. doi: 10.1345/aph.1P757. Epub 2011 Jun 10CrossRefPubMed

86.

Enko D, Wallner F, von-Goedecke A, Hirschmugl C, Auersperg V, Halwachs-Baumann G. The impact of an algorithm-guided management of preoperative anemia in perioperative hemoglobin level and transfusion of major orthopedic surgery patients. Anemia. 2013; 2013:641876. doi: 10.1155/2013/641876

87.

Keeler BD1, Simpson JA, Ng S, Tselepis C, Iqbal T, Brookes MJ, Acheson AG. The feasibility and clinical efficacy of intravenous iron administration for preoperative anaemia in patients with colorectal cancer. Colorectal Dis. 2014 Oct;16(10):794–800. doi: 10.1111/codi.12683CrossRefPubMed

88.

Sowade O1, Messinger D, Franke W, Sowade B, Scigalla P, Warnke H. The estimation of efficacy of oral iron supplementation during treatment with epoetin beta (recombinant human erythropoietin) in patients undergoing cardiac surgery. Eur J Haematol. 1998 Apr;60(4):252–9CrossRefPubMed

89.

García-Erce JA, Cuenca J, Haman-Alcober S, Martínez AA, Herrera A, Muñoz M. Efficacy of preoperative recombinant human erythropoietin administration for reducing transfusion requirements in patients undergoing surgery for hip fracture repair. An observational cohort study. Vox Sang. 2009 Oct;97(3):260–7. doi: 10.1111/j.1423-0410.2009.01200.x. Epub 2009 Jun 3CrossRefPubMed

90.

Muñoz M, Gómez-Ramírez S, Cuenca J, García-Erce JA, Iglesias-Aparicio D, Haman-Alcober S, Ariza D, Naveira E. Very-short-term perioperative intravenous iron administration and postoperative outcome in major orthopedic surgery: a pooled analysis of observational data from 2547 patients. Transfusion. 2014 Feb;54(2):289–99. doi: 10.1111/trf.12195. Epub 2013 Apr 15PubMed

91.

Parker MJ. Iron supplementation for anemia after hip fracture surgery: a randomized trial of 300 patients. J Bone Joint Surg Am. 2010 Feb;92(2):265–9. doi: 10.2106/JBJS.I.00883CrossRefPubMed

92.

Bisbe E, Moltó L2, Arroyo R2, Muniesa JM3, Tejero M3. Randomized trial comparing ferric carboxymaltose vs oral ferrous glycine sulphate for postoperative anaemia after total knee arthroplasty. Br J Anaesth. 2014 Sep;113(3):402–9. doi: 10.1093/bja/aeu092CrossRefPubMed

93.

Auerbach M. Intravenous iron in the perioperative setting. Am J Hematol. 2014 Sep;89(9):933. doi: 10.1002/ajh.23793. Epub 2014 Jul 21. No abstract availableCrossRefPubMed

94.

Keating GM. Ferric carboxymaltose: a review of its use in iron deficiency. Drugs. 2015 Jan;75(1):101–27. doi: 10.1007/s40265-014-0332-3CrossRefPubMed

95.

Gonzalez-Porras JR1, Colado E, Conde MP, Lopez T, Nieto MJ, Corral M. An individualized preoperative blood saving protocol can increase pre-operative haemoglobin levels and reduce the need for transfusion in elective total hip or knee arthroplasty. Transfus Med 2009;19:35–42CrossRefPubMed

96.

Rashiq S, Jamieson-Lega K, Komarinski C, Nahirniak S, Zinyk L, Finegan B. Allogeneic blood transfusion reduction by risk-based protocol in total joint arthroplasty. Can J Anaesth. 2010 Apr;57(4):343–9. doi: 10.1007/s12630-010-9270-zCrossRefPubMed

97.

Beris P, Muñoz M, García-Erce JA, Thomas D, Maniatis A, Van der Linden P. Perioperative anaemia management: consensus statement on the role of intravenous iron. Br J Anaesth. 2008 May;100(5):599–604. doi: 10.1093/bja/aen054. Epub 2008 Mar 27CrossRefPubMed

98.

Spahn DR. Anemia and patient blood management in hip and knee surgery: a systematic review of the literature. Anesthesiology. 2010 Aug;113(2):482–95. doi: 10.1097/ALN.0b013e3181e08e97CrossRefPubMed

99.

Goodnough LT, Maniatis A, Earnshaw P, Benoni G, Beris P, Bisbe E, Fergusson DA, Gombotz H, Habler O, Monk TG, Ozier Y, Slappendel R, Szpalski M. Detection, evaluation, and management of preoperative anaemia in the elective orthopaedic surgical patient: NATA guidelines. Br J Anaesth. 2011 Jan;106(1):13–22. doi: 10.1093/bja/aeq361PubMedCentralCrossRefPubMed

100.

Menkis AH, Martin J, Cheng DC, Fitzgerald DC, Freedman JJ, Gao C, Koster A, Mackenzie GS, Murphy GJ, Spiess B, Ad N. Drug, devices, technologies, and techniques for blood management in minimally invasive and conventional cardiothoracic surgery: a consensus statement from the International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) 2011. Innovations (Phila). 2012 Jul-Aug;7(4):229–41. doi: 10.1097/IMI.0b013e3182747699

101.

Devon KM, McLeod RS. Pre and peri-operative erythropoietin for reducing allogeneic blood transfusions in colorectal cancer surgery. Cochrane Database Syst Rev. 2009 Jan 21;(1):CD007148. doi: 10.1002/14651858.CD007148.pub2

102.

Lin DM, Lin ES, Tran MH. Efficacy and safety of Erythropoietinietin and intravenous iron in perioperative blood management: a systematic review. Transfus Med Rev. 2013 Oct;27(4):221–34. doi: 10.1016/j.tmrv.2013.09.001CrossRefPubMed

103.

Litton E, Xiao J, Ho KM. Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials. BMJ. 2013 Aug 15;347:f4822. doi: 10.1136/bmj.f4822

104.

Hallet J, Hanif A, Callum J, Pronina I, Wallace D, Yohanathan L, McLeod R, Coburn N. The Impact of Perioperative Iron on the Use of Red Blood Cell Transfusions in Gastrointestinal Surgery: A Systematic Review and Meta-Analysis. Transfus Med Rev. 2014 Oct;28(4):205–211. doi: 10.1016/j.tmrv.2014.05.004CrossRefPubMed

105.

Hogan M, Klein AA, Richards T. The impact of anaemia and intravenous iron replacement therapy on outcomes in cardiac surgery. Eur J Cardiothorac Surg. 2014 May 13. doi: 10.1093/ejcts/ezu200

106.

Ghoti H, Rachmilewitz EA, Simon-Lopez R, Gaber R, Katzir Z, Konen E, Kushnir T, Girelli D, Campostrini N, Fibach E, Goitein O. Evidence for tissue iron overload in long-term hemodialysis patients and the impact of withdrawing parenteral iron. Eur J Haematol. 2012 Jul;89(1):87–93. doi: 10.1111/j.1600-0609.2012.01783.xCrossRefPubMed

107.

Rostoker G, Griuncelli M, Loridon C, Magna T, Janklewicz P, Drahi G, Dahan H, Cohen Y. Maximal Standard Dose of Parenteral Iron for Hemodialysis Patients: An MRI-Based Decision Tree Learning Analysis. PLoS One. 2014 Dec 15;9(12):e115096. doi: 10.1371/journal.pone.0115096. eCollection 2014

108.

Nairz M, Haschka D, Demetz E, Weiss G. Iron at the interface of immunity and infection. Front Pharmacol. 2014 Jul 16;5:152. doi: 10.3389/fphar.2014.00152. eCollection 2014. Review

109.

Drakesmith H, Prentice AM. Hepcidin and the iron-infection axis. Science. 2012 Nov 9;338(6108):768–72. doi: 10.1126/science.1224577CrossRefPubMed

110.

Hallberg L, Ryttinger L, Sölvell L. Side-effects of oral iron therapy. A double-blind study of different iron compounds in tablet form. Acta Med Scand Suppl 1966; 459: 3–10PubMed

111.

Rudinskas L, Paton TW, Walker SE, Dotten DA, Cowan DH. Poor clinical response to enteric-coated iron preparations. CMAJ. 1989 Sep 15;141(6):565–6PubMedCentralPubMed

112.

Silverstein SB, Rodgers GM. Parenteral iron therapy options. Am J Hematol 2004;76:74–8. DOI: 10.1002/ajh.20056

113.

Larson DS, Coyne DW. Update on intravenous iron choices. Curr Opin Nephrol Hypertens. 2014 Mar;23(2):186–91. doi: 10.1097/01.mnh.0000441154.40072.2eCrossRefPubMed

114.

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2014 Nov 21. Ferumoxytol versus Other Intravenous Iron Therapies for Anemia: A Review of the Clinical and Cost-effectiveness and Guidelines – An Update [Internet]

115.

Hausmann K, Wulfhekel U, Diillmann J, Kuse R. Iron Storage in Macrophages and Endothelial Cells. Histochemistry, Ultrastructure, and Clinical Significance. Blut 1976;32:289–295CrossRefPubMed

116.

Cassat JE, Skaar EP. Iron in infection and immunity. Cell Host Microbe. 2013 May 15;13(5):509–19. doi: 10.1016/j.chom.2013.04.010PubMedCentralCrossRefPubMed

117.

Bystrom LM, Rivella S. Cancer cells with irons in the fire. Free Radic Biol Med. 2014 May 14. pii: S0891-5849(14)00208–1. doi: 10.1016/j.freeradbiomed.2014.04.035

118.

Rote-Hand-Brief zu intravenösen Eisenpräparaten „VERSCHÄRFTE EMPFEHLUNGEN BEZÜGLICH DES RISIKOS SCHWERER ÜBEREMPFIND-LICHKEITSREAKTIONEN AUF EISEN-PRÄPARATE ZUR INTRAVENÖSEN APPLIKATION“ www.akdae.de/Arzneimittelsicherheit/RHB/Archiv/2013/20131021.pdf

119.

Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, Trelle S, Weingart O, Bayliss S, Djulbegovic B, Bennett CL, Langensiepen S, Hyde C, Engert A. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst. 2006 May 17;98(10):708–14. ReviewCrossRefPubMed

120.

Rodgers GM. A perspective on the evolution of management of cancer- and chemotherapy induced anemia. J Natl Compr Canc Netw 2012;10:434–437PubMed

121.

Keeler BD1, Simpson JA, Ng S, Tselepis C, Iqbal T, Brookes MJ, Acheson AG. Colorectal Dis. 2014 Oct;16(10):794–800. doi: 10.1111/codi.12683. The feasibility and clinical efficacy of intravenous iron administration for preoperative anaemia in patients with colorectal cancer

122.

Baribeault D1, Auerbach M. Iron replacement therapy in cancer-related anemia. Am J Health Syst Pharm. 2011 May 15;68(10 Suppl 1):S4-14; quiz S15–6. doi: 10.2146/ajhp110039

123.

Gafter-Gvili A1, Steensma DP, Auerbach M. Should the ASCO/ASH Guidelines for the use of intravenous iron in cancer- and chemotherapy-induced anemia be updated? J Natl Compr Canc Netw. 2014 May;12(5):657–64PubMed

124.

Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, McDonagh, Parkhomenko A, Tavazzi L, Levesque V, Mori C, Roubert B, Filippatos G, Ruschitzka F, Anker SD; for the CONFIRM-HF Investigators. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2014 Aug 31. pii: ehu385

Titel: Eisen
verfasst von: Priv.-Doz. Dr. med. Dr. rer. nat. Peter Nielsen
Verlag: Springer Berlin Heidelberg
Buch: Transfusionsassoziierte Pharmakotherapie
Print ISBN: 978-3-662-47257-6

Electronic ISBN: 978-3-662-47258-3

Copyright-Jahr: 2016
DOI: https://doi.org/10.1007/978-3-662-47258-3_1

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren

Springer Medizin

1. Eisen

Zusammenfassung

Neu im Fachgebiet AINS

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Hinter dieser Appendizitis steckte ein Erreger

Ärztliche Empathie hilft gegen Rückenschmerzen

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

Update AINS

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neu im Fachgebiet AINS

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Hinter dieser Appendizitis steckte ein Erreger

Ärztliche Empathie hilft gegen Rückenschmerzen

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

Update AINS